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Summary
Epigenetic changes are stable modifications of DNA or
histones that profoundly alter gene expression. They can
be changed by environmental influences and can then be
passed on to daughter cells or via the germ line to offspring.
A variety of changes in epigenetic marks and in the ex-
pression of noncoding RNA has been found in cancer as
well as in chronic inflammatory diseases. Interestingly, in
both diseases similar mechanisms and pathways are affec-
ted albeit often to a different extent. DNA methylation is
often lost in repetitive sequences, while in promoter re-
gions hypo- as well as hypermethylation is found. Changes
in microRNA levels typically affect microRNAs that are
changed by an inflammatory environment, but disease spe-
cific changes have also been found in the blood and various
cell types of patients with rheumatoid arthritis, systemic
lupus erythematosus and other rheumatic diseases. There-
fore, changes in the expression of microRNA in particular,
but also demethylated gene loci, have been proposed as po-
tential biomarkers in chronic inflammatory diseases and in
cancer. Potentially, these changes could be used for early
diagnosis and also to predict treatment response. Unfortu-
nately most studies in rheumatology up to now were not de-
signed to validate these epigenetic changes as biomarkers.
Since the cancer field is much more advanced in the usage
of biomarkers for disease subclassifications and subsequent
therapeutic decisions, it is worthwhile to take a closer look
at the biomarkers, methods and procedures used in onco-
logy and to see which of these could also be applied to pre-
dicting disease severity and therapeutic response in rheum-
atic diseases.
This article will highlight common epigenetic pathways ac-
tivated in cancer and various rheumatic diseases and sum-
marise epigenetic changes that have the potential to be-
come biomarkers in rheumatic diseases.
Key words: epigenetics; biomarker; microRNA;
rheumatology
What is epigenetics?
Throughout the years many different, more or less strict
definitions of epigenetics have been formulated. In a con-
sensus meeting in 2008 in Cold Spring Harbor it was
agreed that an epigenetic trait is a “stably heritable phen-
otype resulting from changes in a chromosome without al-
terations in the DNA sequence” [1]. Wider definitions also
include nonheritable mechanisms [2]. In general, modific-
ations of DNA and histones, as well as noncoding RNA
transcripts and regulation of chromatin accessibility by
nucleosome positioning, are regarded as epigenetic mech-
anisms. Epigenetic marks determine which genes in our
organism are expressed in a particular cell type or activ-
ation state and which are silenced. In contrast to the ge-
netic code, which is more or less stable throughout the
lifetime, epigenetic marks can be altered by environmental
factors, such as toxins or nutrition, and thus allow the cell
to adapt to long-lasting changes in its environment. On the
downside, epigenetic changes induced by the environment
might have detrimental effects and lead to disease devel-
opment. In particular, in diseases with a missing heritabil-
ity and low concordance rates between monozygotic twins,
like many rheumatic diseases, a strong environmental in-
fluence on disease development is assumed. Therefore epi-
genetic changes induced over time, together with a genom-
ic risk background, might lead to disease development and
persistence.
Figure 1
Acetyl (Ac), phospho (P) and methyl (Me) residues are placed on
specific amino acids of the protruding histone tails by writer
proteins. Histone acetyl transferases (HATs) and histone
deacteylases (HDACs) are the readers and writers of acetylation,
respectively. Bromodomains (BRDs) bind acetylated histone tails
and promote the formation of multiprotein complexes. The
methyltransferase EZH2 is bound to long non-coding RNA
(lncRNA), which confers sequence specific location. On the DNA,
ten-eleven translocation (TET) proteins convert methylated
cytosines (mC) to carboxylcytosine (caC), formylcytosine (fC), and
hydroxylmethylcytosine (hmC). Modified from [48] Kyburz D, et al.
Epigenetic changes: the missing link. Best Pract Res Clin.
2014;28(4):577–87, with permission from Elsevier.
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Epigenetic modifications of DNA and histones are placed
directly at the cytosine base of the DNA and at the protrud-
ing tails of the histones, which pack the DNA tightly in-
to nucleosomes (fig. 1). Histone tails can be modified by
numerous histone marks. Up to now histone acetylation,
methylation, phosphorylation, sumoylation, ADP-ribosyla-
tion, ubiquitination, deiminiation/citrullination, proline iso-
merisation and O-GlcNAcylation have been described.
Specific combinations of these different histone modifica-
tions are found at actively transcribed and silenced genes,
respectively. The most studied modification of the DNA
is cytosine methylation, which leads to gene silencing.
Methylation of cytosine is often found in genomic regions
that are rich in cytosine-phosphatidyl-guanine (CpG) di-
nucleotides, so-called CpG islands, in gene promoter re-
gions.
Methylation of cytosine in the DNA mediates the recruit-
ment of transcriptional repressors and interferes with the
binding of transcription factors. The bound repressor pro-
teins can then form complexes with enzymes that place or
remove modifications at the histone tails and thus stabil-
ise DNA methylation-induced gene silencing. Thus, DNA
methylation and histone modifications together reinforce
dense packing and silencing of chromatin. In contrast to
DNA methylation, however, some histone marks are also
associated with actively transcribed chromatin, most prom-
inently histone acetylation. The effect of histone modific-
ations on gene expression is believed to be mediated by
structural changes that alter accessibility of the transcrip-
tion machinery to gene promoters as well as by recruitment
of reader proteins that then form complexes with gene ac-
tivating and repressive proteins. Even though the techno-
logy to study histone modifications has substantially im-
proved in recent years, the complexity and dynamics of
these epigenetic marks are far from being fully understood.
DNA methylation is crucial for the silencing of retrotrans-
posable elements in the genome, inactivation of the second
X chromosome in female cells and tissue specific gene ex-
pression. Accordingly, DNA methylation patterns have to
be very stable and are faithfully restored after cell division.
Nevertheless, changes in DNA methylation are commonly
found in tumour cells and increasing numbers of studies
have also found epigenetic changes in chronic inflammat-
ory diseases [3–5]. In most cases, a state of global hypo-
methylation that mainly affects areas of repeated DNA ele-
ments such as long interspersed nuclear elements (LINE)-1
is combined with hypo- and hypermethylation in gene en-
coding areas [6–9]. Hypermethylation in tumour cells has
been suggested to be either random due to aberrant activity
of DNA methyltransferases (DNMTs) or selective due to
guidance of DNMTs to DNA loci with specific cis features
[10]. Studies of differentially methylated loci in promoters,
5’/3’ untranslated regions and gene bodies in synovial
fibroblasts of rheumatoid arthritis (RA) patients suggest
that differentially methylated genes are not random, but
rather enriched for certain pathways, which supports a se-
lective pathway introducing changes of DNA methylation
in RA [11, 12]. In immune cells from patients with system-
ic lupus erythematosus (SLE), hypomethylated genes were
enriched in interferon pathways, also pointing to selective
loss of methylation [13]. Interestingly, CD4 T cells of pa-
tients with Sjögren’s syndrome also showed hypomethyla-
tion of genes of the interferon signature [14].
A mechanism for the global loss of methylation seen in re-
petitive genomic sequences in cancer as well as in chron-
ic inflammation has been connected to the increased con-
sumption of polyamines caused by increased rates of pro-
liferation and cell growth [15–17]. Polyamine recycling
and DNA methylation use S-adenosylmethionine as donor
for the methyl group. Activated polyamine metabolism
therefore can lead to a shortage of S-adenosylmethionine
for the restoration of methyl marks after cell division, res-
ulting in DNA hypomethylation of the daughter cells. Re-
cent studies also showed that cytosine methylation can be
converted to hydroxymethyl-cytosine, formyl-cytosine and
carboxyl-cytosine by ten-eleven translocation (TET) en-
zymes [18]. Changes in TET expression in cancer and in-
flammation are therefore also assumed to promote changes
in DNA methylation marks [19, 20].
In many tumours and chronic diseases, histone modifica-
tions, as well as the enzymes that write, read and erase
these modifications, have been described as altered [21,
22]. Whether these changes are caused by altered genomic
structures and changes in cell growth and metabolism in
these conditions or are actually causing altered cell beha-
viour is still under debate.
New insights into how histone marks are placed at specific
genomic loci has been gained through the study of long
noncoding RNAs (lncRNA). LncRNAs form complexes
with histone-modifying enzymes and guide them to a spe-
cific site in the genome in cis (at the site of their transcrip-
tion) or in trans by binding DNA at a distant genomic site.
Also, small noncoding RNAs, such as microRNAs, play
an important role in the regulation of gene expression. Mi-
croRNA is only around 22 nucleotides long and can spe-
cifically bind to complimentary regions of messenger RNA
(mRNA), thereby inhibiting its translation, i.e. protein pro-
duction. It is suggested that the human genome encodes
more than 25000 microRNAs. One microRNA can bind
to several target mRNAs and in turn one mRNA can be
targeted by several microRNAs [23]. Many of these mi-
croRNAs are human and tissue specific, which makes them
difficult to study in animal models, but also makes them
particularly interesting in regard to disease development.
In RA and other rheumatic diseases microRNAs have been
shown to be altered in different cells types, as well as in
serum and synovial fluid, and are considered to influence
major disease pathogenic pathways in stromal and immune
cells (for review see [24]).
Why epigenetic biomarkers?
Epigenetic modifications have not only been recognised as
master regulators of many essential pathways in the cell,
but have also been tested as potential biomarkers for dis-
ease states and treatment response. Epigenetic biomark-
ers have mainly been tested in the cancer field [25, 26].
However, in rheumatology we can learn from these studies
regarding discovery approaches and measuring techniques,
and we can envisage how epigenetic biomarkers could be
used in the diagnosis and prognosis of rheumatic diseases.
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In contrast to the cancer field, in rheumatology the usage of
genetic biomarkers is very limited, since disease develop-
ment is in the majority of cases not connected with a spe-
cific genomic mutation. Clinically relevant genetic markers
such as HLA-B27 in spondyloarthritides or the shared epi-
tope in RA can help to support a diagnosis in patients with
symptoms. However, more than 95% of HLA-B27 positive
individuals will never develop disease and around 30% of
the healthy population carries the shared epitope.
One explanation for disease development in only a minor-
ity of the risk HLA subtypes might be changes in DNA
methylation. Liu et al. identified several differentially
methylated regions in the major histocompatibility com-
plex (MHC) region [encoding for human leucocyte an-
tigens (HLA)] in peripheral blood mononuclear cells
(PBMCs) of RA patients, which were connected to RA risk
single nucleotide polymorphisms (SNPs) [27]. The authors
suggest that these changes in methylation mediate the ge-
netic risk for developing RA, at least in regard to the MHC
region. In order to see whether more genetic risk loci are af-
fected by differential methylation and thus gain penetrance,
other disease-relevant cell types, such as synovial fibro-
blasts, have also to be analysed in a similar way. Given the
relatively weak connection between genetic background
and rheumatic diseases, it has long been assumed that ge-
netically predisposed individuals are affected by additional
environmental factors that then lead to disease develop-
ment. If we assume that epigenetic changes are induced
by these causative environmental influences, alterations of
epigenetic marks might be an early sign of disease devel-
opment.
A major problem in biomarker discovery, in cancer as well
as in rheumatic diseases, is the fact that disease-specific
changes are accompanied by a strong nonnspecific inflam-
matory response [28]. Thus, many factors, such as simple
C-reactive protein measurements can differentiate between
healthy individuals and cancer patients or RA patients, but
they are of little diagnostic, let alone prognostic value due
to lack of specificity. Levels of interleukin-6 (IL-6), for in-
stance, are increased in a number of pathological condi-
tions, including RA. In RA patients, however, it could be
shown that the promoter region of IL-6 is hypomethylated
in PBMCs [29]. Even though elevated IL-6 levels are not
specific, this loss of DNA methylation in the IL-6 promoter
in PBMCs might be quite specific for RA patients. Un-
fortunately, epigenetic analysis of mixed cell populations
such as PBMCs holds the risk that changes in cell com-
position are detected rather than changes at specific gen-
omic sites. Furthermore, in this study RA PBMCs were
only compared with healthy controls and not with PBMCs
from patients with other chronic inflammatory conditions.
Nevertheless, this example shows that even though a mo-
lecule might lack specificity to be used as biomarker, the
reason for its increased expression might be quite specific.
We know already that epigenetic changes cause altered ex-
pression of many factors in different cell types in rheum-
atic diseases and the appearance of these epigenetic marks
is most probably more specific for rheumatic diseases than
the expression of their target molecules. However, well-de-
signed studies to prove this point are urgently needed (fig.
2).
Which epigenetic markers could be
useful in rheumatology?
To date, almost all epigenetic biomarkers used in clinics
come from cancer research, and DNA methylation marks
are the most commonly used [30]. DNA methylation is
stable and can even be measured in cell-free DNA in body
fluids [31]. As mentioned above, several differentially
methylated regions have been described in rheumatic dis-
eases in various cell types. Already in the early 1990s a
loss of DNA methylation was described in blood cells and
synovial tissues of RA and SLE patients [32, 33]. Many re-
ports of changes in DNA methylation, genome wide and
at specific genomic sites, followed [7–9, 11, 12, 34, 35].
The earliest studies measured the total content of methyl-
ated cytosine in DNA of synovial fibroblasts and immune
cells of RA and SLE patients, and found global DNA hy-
pomethylation, which is similar to findings in cancer cells
and most probably due to loss of methylation in repetitive
sequences of the genome [7, 32, 33]. Later studies either
looked at specific promoter sites, for example synovial
fibroblasts of RA patients, or used array technology to ana-
lyse thousands of preselected methylation sites mainly in
and around coding regions, but also in noncoding regions
or regions encoding for microRNA [8, 9, 11, 12, 34, 36].
These studies found hypomethylated and hypermethylated
regions, which points to a general disturbance of the epi-
genetic machinery in RA similar to findings in cancer cells
[6]. In systemic sclerosis also, hypo- and hypermethyl-
ated regions were found in dermal fibroblasts and blood
cells [37–39]. Interestingly, in blood cells from SLE pa-
tients, hypermethylation events are rarely found and hypo-
methylation seems to predominate [13]. This is also in line
with studies showing that treatment of T cells with DNA
demethylating agents can induce lupus-like symptoms in
mice [40]. These results point towards a causative role
for epigenetic changes in lupus. Studies in synovial fibro-
blasts from RA patients at a very early stage of disease also
support the hypothesis that loss of DNA methylation, at
least in synovial fibroblasts, has already occurred at a time
point when destructive processes are not yet manifest and
therefore could be causative [35, 41]. While these studies
showed promising results, the question whether epigenetic
changes are causes or consequences of chronic inflamma-
tion is not yet solved and the usage of DNA methylation as
diagnostic biomarker in rheumatic diseases must be further
followed up. Particularly needed are studies that analyse
DNA methylation in peripheral blood cells from patients in
the early stages of rheumatic diseases where late changes in
DNA methylation have already been shown, and comparis-
Figure 2
The development of a clinically useful biomarker requires several
separate studies and analysis. Unfortunately in rheumatology most
of the biomarker studies are in the discovery phase, but have
neither been validated nor tested for their feasibility.
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ons of DNA methylation not with healthy controls but with
other rheumatic diseases. One such study recently showed
that measurement of DNA methylation in the IFI44L pro-
moter in whole blood could separate SLE patients from RA
and systemic sclerosis patients with a sensitivity and speci-
ficity of around 90% [42].
Recent studies also explored changes in DNA methylation
as biomarker for treatment response [20, 43, 44]. None of
the currently used therapies for RA are effective in all pa-
tients. In practice this means several months of expensive
treatment with potential severe side effects and with no be-
nefit for a substantial percentage of RA patients. There is
an urgent need for biomarkers to stratify these patients be-
fore initiation of treatment, or at least to detect response
faster than the currently used clinical measures. The fact
that methotrexate treatment was found to influence DNA
methylation gives hope that assessing affected DNA loci
before and after treatment might be useful as predictor and/
or early measure for response to treatment [20, 44].
Also certain histone modifications and histone-modifying
enzymes were found to be altered in rheumatic diseases
[45]. However, at the moment histone modifications at spe-
cific sites are still technically much more difficult to meas-
ure than DNA methylation. It is also not clear how stable
these histone modifications are, throughout the disease as
well as in the biological sample that is used for testing.
Ideally a biomarker should be as robust as possible and re-
liably measurable with different methods and in different
settings. Therefore histone modifications do not appear as
ideal candidates for biomarkers at the moment.
MicroRNAs on the other hand fulfil most of the require-
ments of a biomarker. Their expression has been shown to
be tissue- and disease-specific, they are very stable, and
can easily be measured in tissues as well as body fluids by
polymerase chain reaction (PCR) or array technology [24,
46]. Not surprisingly, in rheumatic diseases many of the
microRNAs that are known to be induced or inhibited by
an inflammatory environment, so called ‘inflamma-miRs’
such as miR-155 and miR-146a have been shown to be
altered [47–51]. MicroRNA profiles measured in the ser-
um/plasma of patients show significant changes of various
microRNAs in RA, as well as in SLE, juvenile idiopath-
ic arthritis and in systemic sclerosis [52–55]. Whether their
expression levels are sufficiently sensitive and specific for
them to be used as biomarkers remains to be proven, since
the studies conducted up to now were not designed to val-
idate microRNAs as diagnostic biomarkers.
Several recent studies identified microRNAs that predicted
therapeutic response in RA patients [56–58]. Krintel et
al. showed that patients with low levels of miR-22 and
high levels of miR-886-3p, measured in whole blood be-
fore initiation of therapy, can benefit more from treatment
with adalimumab [57]. In the study of Duroux-Richard et
al., high levels of miR-125b in whole blood at baseline
predicted good response to rituximab treatment [58]. In
both studies high/low expression in responders was defined
as significantly different from that of nonresponders.
However, for the use of microRNA as biomarker in an in-
dividual patient a clear separation of expression of the mi-
croRNA to a previously defined normal range of expres-
sion must be given. Such analyses have not been done in
any study so far. Also, bigger cohorts are needed to valid-
ate these published results.
Summary and outlook
In summary, epigenetic biomarkers have entered the cancer
field already and are also starting to be analysed in rheum-
atology. Even though the field is still in its infancy, studies
regarding DNA methylation and microRNA measurements
in particular are promising. However, to further advance
this field, studies have to be conducted that are specifically
designed to validate the use of epigenetic changes and mi-
croRNA as prognostic or diagnostic biomarkers.
In patients with glioblastoma, promoter methylation of the
DNA repair gene O6-methylguanine-DNA methyltrans-
ferase (MGMT) is already used in clinics to predict the
response to alkylating drugs, which shows that the use
of DNA methylation as epigenetic biomarker is feasible.
Methylation-specific PCR, as well as pyrosequencing, can
be applied to measure the methylation status of a specific
locus, with the first being cheap and fast and the latter be-
ing more reliable, but also more expensive. In rheumatic
diseases the status of DNA methylation could be assessed
in biopsies from synovial tissues of patients, in peripheral
blood cells or even in cell-free DNA isolated from the
blood, which is currently being explored in cancer patients
[59].
In view of the costs that are spent on drugs in rheumatology
and the time some patients have to wait for their diagnosis
and efficient treatment, it is absolutely justified to intensify
efforts to find the right diagnosis and the right treatment.
This may mean that more biopsies have to be taken and
more than one biomarker has to be measured – measures
that are readily accepted for cancer diagnosis.
Efforts like the Encyclopedia Of DNA Elements
(ENCODE) project, which aims to identify all functional
elements of the genome including histone modifications
and DNA methylation, have already brought valuable in-
sights into transcript expression and are requisite for the
understanding of the alterations in the epigenome that are
measured in rheumatic diseases. But to understand epigen-
etic changes in rheumatic diseases is probably not enough.
As in the cancer genome atlas (TCGA), the rheumatology
research community should aim to map molecular path-
ways that drive rheumatic diseases and connect changes in
the genome, the epigenome, transcription, protein expres-
sion and clinical outcomes. Potential biomarkers or com-
bination of biomarkers must then be selected and tested
in studies with an appropriate study design. This strategy
would not only bring us closer to finding diagnostic, pre-
dictive and prognostic biomarkers, but would also help to
find new therapeutic targets.
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Figure 1
Acetyl (Ac), phospho (P) and methyl (Me) residues are placed on specific amino acids of the protruding histone tails by writer proteins. Histone
acetyl transferases (HATs) and histone deacteylases (HDACs) are the readers and writers of acetylation, respectively. Bromodomains (BRDs)
bind acetylated histone tails and promote the formation of multiprotein complexes. The methyltransferase EZH2 is bound to long non-coding
RNA (lncRNA), which confers sequence specific location. On the DNA, ten-eleven translocation (TET) proteins convert methylated cytosines
(mC) to carboxylcytosine (caC), formylcytosine (fC), and hydroxylmethylcytosine (hmC). Modified from [48] Kyburz D, et al. Epigenetic changes:
the missing link. Best Pract Res Clin. 2014;28(4):577–87, with permission from Elsevier.
Figure 2
The development of a clinically useful biomarker requires several separate studies and analysis. Unfortunately in rheumatology most of the
biomarker studies are in the discovery phase, but have neither been validated nor tested for their feasibility.
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